US › Healthcare

Sera Prognostics Inc (SERA)

US · Healthcare · Medical Devices

$1.93-8.10%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$14,000
Revenue YoY
-63.2%
Net profit
$-8.4M
Profit YoY
-2.6%
EPS
$-0.17
EPS estimate
$-0.17
Net margin
-59,992.9%

EPS came in at -0.17 against a street estimate of -0.17 — a beat of 0.0%.

Key statistics

Market cap
$82.2M
Forward P/E
0.0
P/B
1.20
Book value
$1.73
EPS (TTM)
$-0.64
52-week high
$3.95
52-week low
$1.56
50-day MA
$2.01
200-day MA
$2.52
Beta
0.98

Analyst view

Analysts rate Sera Prognostics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $5.50.

Shareholding

Insiders
11.89%
Institutions
51.57%

Largest institutional holders

FundStake
Baker Bros Advisors LP14.04%
Whetstone Capital Advisors, LLC8.44%
Aberdeen Group PLC6.51%
Vivo Capital, LLC4.21%
Vanguard Capital Management, LLC3.08%
CapTrust Financial Advisors1.37%
Geode Capital Management, LLC0.93%
Citadel Advisors Llc0.64%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sera Prognostics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.